PuraMed BioScience announced its plans to initiate testing of a new hemp-based epilepsy treatment in the 4th quarter of 2014.

The company plans to develop a sublingual formulation, which offers faster delivery and efficiency. Sublingual delivery also avoids the “first pass effect” that often degrades oral drugs.

RELATED: Medical Marijuana Could Help MS Patients

In March 2014, the company set out to develop and manufacture hemp and THC-free formulations that created medicinal compounds without the “high” associated with THC-containing cannabis. The company has researched the potential efficacy of cannabinoid-based pain treatment for patients with rheumatoid arthritis and chronic back pain and found that there was high probability of success.

PuraMed BioScience is also rebranding its flagship product LipiGesic M as MigraPure.

For more information call (715) 339-6373 or viist PuraMedBioScience.comg.